Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Kubicki T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Kubicki T, et al. Among authors: lojko dankowska a. Pol Arch Intern Med. 2024 May 28;134(5):16749. doi: 10.20452/pamw.16749. Epub 2024 May 14. Pol Arch Intern Med. 2024. PMID: 38747414 Free article. Clinical Trial. No abstract available.
Evaluation of elafin as a marker of skin fibrosis -a preliminary study.
Polanska A, Kowalczyk MJ, Olewicz-Gawlik A, Łojko-Dankowska A, Walecka I, Ciechanowicz P, Żaba R, Dańczak-Pazdrowska A. Polanska A, et al. Among authors: lojko dankowska a. Arch Dermatol Res. 2024 May 9;316(5):150. doi: 10.1007/s00403-024-02881-w. Arch Dermatol Res. 2024. PMID: 38724860 No abstract available.
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Przybyłowicz-Chalecka A, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Jiang K, Cooperrider JH, Jakubowiak AJ, Derman BA. Kubicki T, et al. Among authors: lojko dankowska a. Blood. 2024 Aug 29;144(9):955-963. doi: 10.1182/blood.2024024041. Blood. 2024. PMID: 38713888 Free PMC article. Clinical Trial.
Gender and the length of time since autologous hematopoietic stem cell transplantation-What is their influence on the immune reconstitution in multiple myeloma patients?
Popierz-Rydlewska N, Merkiel-Pawłowska S, Łojko-Dankowska A, Komarnicki M, Chalcarz W. Popierz-Rydlewska N, et al. Among authors: lojko dankowska a. PLoS One. 2023 Dec 7;18(12):e0295308. doi: 10.1371/journal.pone.0295308. eCollection 2023. PLoS One. 2023. PMID: 38060495 Free PMC article.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Kubicki T, et al. Among authors: lojko dankowska a. Br J Haematol. 2023 Dec;203(5):792-802. doi: 10.1111/bjh.19097. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691005 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: lojko dankowska a. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity.
Dankowski R, Sacharczuk W, Łojko-Dankowska A, Nowicka A, Szałek-Goralewska A, Szyszka A. Dankowski R, et al. Among authors: lojko dankowska a. Kardiol Pol. 2021;79(9):1040-1041. doi: 10.33963/KP.a2021.0052. Epub 2021 Jul 6. Kardiol Pol. 2021. PMID: 34227674 Free article. No abstract available.
16 results